Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 6/20 | 0.49 |
| ▸ | PIM3 | Q86V86 | 5/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | AKT1 | P31749 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.48 |
| ▸ | CDC7 | O00311 | 2/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.48 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.48 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.44 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.44 |
| ▸ | GSK3A | P49840 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4219756 | 0.88 | PIM1 (0.53) | PIM1PIM3CHEK1AKT1FLT3 | |
| SCHEMBL4215069 | 0.82 | ALDH1A1 (0.53) | PIM1PIM3PIM2CDC7CSNK2A1 | |
| SCHEMBL4207625 | 0.82 | PARP1 (0.49) | PIM1PIM3PIM2CDC7CSNK2A1 | |
| SCHEMBL4208127 | 0.79 | LIMK1 (0.59) | PIM1PIM3PIM2CDC7CSNK2A1 | |
| SCHEMBL4208864 | 0.78 | KRAS (0.51) | PIM1PIM3PIM2CDC7CSNK2A1 | |
| SCHEMBL2307979 | 0.77 | HTT (0.51) | PIM1PIM3CHEK1AKT1FLT3 | |
| SCHEMBL4208101 | 0.75 | PARP1 (0.41) | PIM1PIM3PIM2CDC7CSNK2A1 | |
| SCHEMBL2302798 | 0.75 | KDM4A (0.51) | PIM1PIM3PIM2CDC7CSNK2A1 | |
| SCHEMBL4207979 | 0.73 | PARP1 (0.53) | PIM1PIM3CHEK1PIM2CDC7 | |
| SCHEMBL4213078 | 0.73 | PIM1 (0.59) | PIM1PIM3PIM2CDC7CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | claimed |
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | PIM1, PIM3, PIM2 | PIM1 1/4885PIM3 2/4885CHEK1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.